A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Trial status:Recruiting
Trial ID:
BNT323-01
NCT ID:
EudraCT ID:
N/A
EU Trial (CTIS) Number:
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial Details
The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population with prior immune checkpoint inhibitor (ICI) treatment.
Medical Condition
Trial Drug
See more
Phase
Phase 3
Type
Interventional
Estimated Enrolment
504
Estimated Trial Date
Jun 2025 - Mar 2028
Trial Participant Requirements
Age
18+ years
Sex
Female
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Sunshine Hospital
Saint Albans, Australia, 3021
Status
Recruiting
Location
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China, 515031
Status
Recruiting
Location
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Status
Recruiting
Location
Jiangxi Maternal and Child Health Hospital
Nanchang, Jiangxi, China, 330006
Status
Recruiting
Location
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Status
Recruiting
Location
China Medical University Hospital
Taichung, Taiwan, Province of China, 404
Status
Recruiting
Go to page